Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
Inflammation plays a major role in the pathophysiology of COVID-19, and corticosteroids are validated as initial potent broad-spectrum anti-inflammatory agents. IL-6 is one of the culprit pro-inflammatory cytokines identified for this cytokine storm. Tocilizumab is a recombinant humanized monoclonal...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-01-01
|
| Series: | Apollo Medicine |
| Subjects: | |
| Online Access: | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2021;volume=18;issue=3;spage=189;epage=191;aulast=Bansal |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846095565479215104 |
|---|---|
| author | Sameer Bansal Uma Karjigi Ravindra M Mehta |
| author_facet | Sameer Bansal Uma Karjigi Ravindra M Mehta |
| author_sort | Sameer Bansal |
| collection | DOAJ |
| description | Inflammation plays a major role in the pathophysiology of COVID-19, and corticosteroids are validated as initial potent broad-spectrum anti-inflammatory agents. IL-6 is one of the culprit pro-inflammatory cytokines identified for this cytokine storm. Tocilizumab is a recombinant humanized monoclonal antibody that inhibits binding of interleukin (IL)-6 to both membrane and soluble IL-6 receptors. The role of tocilizumab was controversial with conflicting evidence, but recent data validate the use of this agent under specific circumstances of rapidly worsening COVID acute respiratory distress syndrome with escalating respiratory support or gradually worsening COVID-19 pneumonia in a hospital setting. One of the benchmark tocilizumab studies is the REMAP-CAP trial that showed the benefit of IL-6 antagonists in terms of survival, number of organ support-free days, and even probability of discharge from the hospital. This benefit was seen when tocilizumab was administered within 24 h of patients requiring either respiratory or hemodynamic support. A recently concluded meta-analysis showed that tocilizumab treatment predicts better overall survival in COVID-19 patients (hazard ratio [HR] =0.45, 95% confidence interval [CI]: 0.24–0.84, P = 0.01), especially in severe cases (HR = 0.58, 95% CI: 0.49–0.68, P < 0.00001). |
| format | Article |
| id | doaj-art-2385fbd5fad7415394d40d870324d83e |
| institution | Kabale University |
| issn | 0976-0016 2213-3682 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Apollo Medicine |
| spelling | doaj-art-2385fbd5fad7415394d40d870324d83e2025-01-02T10:10:58ZengSAGE PublishingApollo Medicine0976-00162213-36822021-01-0118318919110.4103/am.am_88_21Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumoniaSameer BansalUma KarjigiRavindra M MehtaInflammation plays a major role in the pathophysiology of COVID-19, and corticosteroids are validated as initial potent broad-spectrum anti-inflammatory agents. IL-6 is one of the culprit pro-inflammatory cytokines identified for this cytokine storm. Tocilizumab is a recombinant humanized monoclonal antibody that inhibits binding of interleukin (IL)-6 to both membrane and soluble IL-6 receptors. The role of tocilizumab was controversial with conflicting evidence, but recent data validate the use of this agent under specific circumstances of rapidly worsening COVID acute respiratory distress syndrome with escalating respiratory support or gradually worsening COVID-19 pneumonia in a hospital setting. One of the benchmark tocilizumab studies is the REMAP-CAP trial that showed the benefit of IL-6 antagonists in terms of survival, number of organ support-free days, and even probability of discharge from the hospital. This benefit was seen when tocilizumab was administered within 24 h of patients requiring either respiratory or hemodynamic support. A recently concluded meta-analysis showed that tocilizumab treatment predicts better overall survival in COVID-19 patients (hazard ratio [HR] =0.45, 95% confidence interval [CI]: 0.24–0.84, P = 0.01), especially in severe cases (HR = 0.58, 95% CI: 0.49–0.68, P < 0.00001).http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2021;volume=18;issue=3;spage=189;epage=191;aulast=Bansalcovid-19interleukin 6tocilizumab |
| spellingShingle | Sameer Bansal Uma Karjigi Ravindra M Mehta Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia Apollo Medicine covid-19 interleukin 6 tocilizumab |
| title | Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia |
| title_full | Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia |
| title_fullStr | Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia |
| title_full_unstemmed | Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia |
| title_short | Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia |
| title_sort | tocilizumab a potent immunomodulatory agent in the treatment of covid 19 pneumonia |
| topic | covid-19 interleukin 6 tocilizumab |
| url | http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2021;volume=18;issue=3;spage=189;epage=191;aulast=Bansal |
| work_keys_str_mv | AT sameerbansal tocilizumabapotentimmunomodulatoryagentinthetreatmentofcovid19pneumonia AT umakarjigi tocilizumabapotentimmunomodulatoryagentinthetreatmentofcovid19pneumonia AT ravindrammehta tocilizumabapotentimmunomodulatoryagentinthetreatmentofcovid19pneumonia |